Skip to content

Study · Not a test of the peptide alone · 2023

1 result

Schisanhenol Attenuates OxLDL-Induced Endothelial Dysfunction via an AMPK-Dependent Mechanism.

Chiu TH, Ku CW, Ho TJ, Tsai KL, Hsu WC, Chen YA, Ou HC, Chen HI

The American journal of Chinese medicine29 Jul 2023Cited by 7 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking AICAR (acadesine).

  1. 01LabNot a test of AICAR (acadesine) aloneIn vitro (cells)Mechanism

    In HUVECs, experiments using AICAR and other probes supported AMPK involvement in SAL inhibition of oxLDL-induced NADPH oxidase assembly and ROS generation.

    In plain wordsIn cells, experiments using AICAR and other probes supported an AMPK mechanism for SAL antioxidant effects.

    Outcome
    Not applicableAMPK involvement in SAL antioxidant effects
    Study

    humann: not reported in source

    oxLDL-treated human umbilical vein endothelial cells
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    This effect was further confirmed using knockdown AMPK with small interfering RNA (siRNA) and pharmaceutical reagents, such as the AMPK activator (AICAR), PKC inhibitor (Gö 6983), and ROS inhibitor (DPI).
    2 context sentences
    Summary · context
    In addition, SAL treatment led to an inhibiting effect on the oxLDL-induced membrane assembly of NADPH oxidase subunits, and a similar effect was observed in ROS generation.
    Summary · context
    In this study, human umbilical vein endothelial cells (HUVECs) were pre-treated with SAL and oxLDL.

    In this study, AICAR (acadesine) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking AICAR (acadesine).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.